Current and future directions in mammalian target of rapamycin inhibitors development.
about
Targeting JAK2 in the therapy of myeloproliferative neoplasmsDual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancerSirolimus, a promising treatment for refractory Kaposiform hemangioendothelioma.Inducing autophagy by rapamycin before, but not after, the formation of plaques and tangles ameliorates cognitive deficits.A review on various targeted anticancer therapies.Targeting mTORC1-mediated metabolic addiction overcomes fludarabine resistance in malignant B cells.Perifosine enhances mTORC1-targeted cancer therapy by activation of GSK3β in NSCLC cells.Clinical application of development of nonantibiotic macrolides that correct inflammation-driven immune dysfunction in inflammatory skin diseasesTargeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future PerspectivesTargeting the PI3K signaling pathway in cancer therapy.Onychopathy induced by temsirolimus, a mammalian target of rapamycin inhibitor.The promise of mTOR inhibitors in the treatment of colorectal cancer.Everolimus in colorectal cancer.PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer.mTOR inhibitor-induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm.Potential Therapeutic Roles for Inhibition of the PI3K/Akt/mTOR Pathway in the Pathophysiology of Diabetic Retinopathy.PI3K/mTOR pathway inhibitors sensitize chronic myeloid leukemia stem cells to nilotinib and restore the response of progenitors to nilotinib in the presence of stem cell factor.Combined effects of PI3K and SRC kinase inhibitors with imatinib on intracellular calcium levels, autophagy, and apoptosis in CML-PBL cells.Phase I study of vinblastine and sirolimus in pediatric patients with recurrent or refractory solid tumors.Novel benzopyran derivatives and their therapeutic applications: a patent review (2009-2016).An orthotopic model of metastatic nasopharyngeal carcinoma and its application in elucidating a therapeutic target that inhibits metastasis.Inhibition of Mammalian target of rapamycin in human acute myeloid leukemia cells has diverse effects that depend on the environmental in vitro stress.Loss of pSer2448-mTOR expression is linked to adverse prognosis and tumor progression in ERG-fusion-positive cancers.Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.
P2860
Q26860796-AE1B2D50-5319-48B9-9DD6-05FE18EC4531Q27324821-543C30FF-3AB2-4536-AB6A-237464BB658AQ33412904-D6AD238E-A606-4175-BB71-C176EB70E430Q34043165-98C293CF-8204-4BF9-99BA-CB67A7B77569Q34164735-C29D0312-E300-4A24-B7FC-E08703FC301AQ34177843-489706CA-B98F-4046-A802-0F7C6FE879BCQ36289873-D5A46429-DBDA-45F2-AF50-8E4DEB6D0AD0Q36425959-D92884C5-4DC2-45D9-B9C4-83B64C74D037Q37132788-2C342808-0350-4DA3-81EB-CDDCA79F0B78Q37975242-1825304F-643D-4F87-BBFD-7FDBE756FFA2Q38012000-C64F3AD3-4C7C-4F2C-B042-E83B28F75146Q38043507-EE6843E3-39A2-4BFB-A550-F6F874D97C05Q38081233-9A8C0350-2788-4E59-865E-71E63DCA4270Q38236320-AF71182C-4E5B-46BA-97ED-A01841470850Q38603164-91949782-822E-4ECE-8026-8EF6693A0CC7Q38895113-46C1C43C-C82E-42BC-A8E1-4D16DA68A44DQ39087858-742C2AD6-F48F-40CF-ABBB-97FDDA21A1DEQ39106999-EF8323C9-DCB0-4630-AA5F-1D2434686EA7Q39365297-A97A970E-F156-4034-BA25-30EDBC8058D6Q39382164-9D131760-BD57-48F2-A0A1-BDAED9362839Q41865036-66F20CD2-3B13-4700-B0F7-CD670A5BC035Q41965978-C77AB793-C0A1-40B6-B2B1-4AC510B0DF84Q45253711-FCF54132-151E-4F40-8ACD-36C0745DB9F6Q54558691-5340537A-8539-477D-9DE5-F312FD4FFC20
P2860
Current and future directions in mammalian target of rapamycin inhibitors development.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 February 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Current and future directions in mammalian target of rapamycin inhibitors development.
@en
Current and future directions in mammalian target of rapamycin inhibitors development.
@nl
type
label
Current and future directions in mammalian target of rapamycin inhibitors development.
@en
Current and future directions in mammalian target of rapamycin inhibitors development.
@nl
prefLabel
Current and future directions in mammalian target of rapamycin inhibitors development.
@en
Current and future directions in mammalian target of rapamycin inhibitors development.
@nl
P2860
P1476
Current and future directions in mammalian target of rapamycin inhibitors development.
@en
P2093
Angelica Fasolo
Cristiana Sessa
P2860
P304
P356
10.1517/13543784.2011.541154
P407
P577
2011-02-08T00:00:00Z